As of 2025-12-19, the Intrinsic Value of Summit Therapeutics Inc (SMMT) is -1.19 USD. This SMMT valuation is based on the model Peter Lynch Fair Value. With the current market price of 17.04 USD, the upside of Summit Therapeutics Inc is -107.01%.
Based on its market price of 17.04 USD and our intrinsic valuation, Summit Therapeutics Inc (SMMT) is overvalued by 107.01%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -1.19 - -1.19 | -1.19 | -107.01% |
| P/E | (1.81) - (3.39) | (2.50) | -114.7% |
| DDM - Stable | (1.31) - (3.46) | (2.39) | -114.0% |
| DDM - Multi | (0.18) - (0.38) | (0.25) | -101.5% |
| Market Cap (mil) | 12,685.26 |
| Beta | 1.53 |
| Outstanding shares (mil) | 744.44 |
| Enterprise Value (mil) | 12,446.70 |
| Market risk premium | 4.60% |
| Cost of Equity | 13.48% |
| Cost of Debt | 5.00% |
| WACC | 8.57% |